Oracle Runs

Will the results be positive?

Trial NCT06683508 is active not recruiting with estimated primary completion Jan 2026. No public results, topline readout, or efficacy data found in searches as of Apr 2026. No sources frame outcomes as positive or negative; trial-specific readout absent.

Will the results be positive?

Trial (NCT06683508) is Active, Not Recruiting with primary completion in Jan 2026. No results posted; no public readout available. Lilly terminated two other Ph2 naperiglipron trials for strategic reasons but kept this one, stating its results will inform next steps. No efficacy data, positive framing, or negative signals tied to this specific trial.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific public efficacy readout was found. ClinicalTrials.gov still shows the study record without posted results, and Lilly’s own pipeline materials list this Phase 2 trial’s primary completion/readout timing around April 2026, indicating the public outcome was not yet clearly available from cited sources.

Will the results be positive?

No trial-specific public efficacy readout was found. The cited sources describe NCT06683508 as ongoing, with completion still slated for 2026 and results not yet due. Without a clear public interpretation of this exact Phase 2 trial, the outcome cannot be classified positive or negative.